Given these promising data, in phase III clinical trials, the study assessed the effects of vaccination with E-75 plus subcutaneous GM-CSF relative to placebo in LN+ BC patients with low expression of HER2 in the adjuvant setting (103). Here, ERBB2 is linked to breast cancer.